Gentris works with customers to create biomarker assays, define patient-responder recruitment criteria, and design protocols with improved end-points while reducing clinical trial costs and enhancing the probability of commercial success.
Gentris validated IL28B as a novel biomarker to measure efficacy responses in new hepatitis C therapies.